Should we also evaluate SET together with CIP2A for the treatment with second-generation tyrosine kinase inhibitors in chronic myeloid leukemia?
Translational Oncology Division, Oncohealth Institute, IIS-Fundación Jiménez Diaz, UAM, University Hospital 'Fundación Jiménez Diaz', Madrid, Spain.
I
I
Cristóbal
Pathology Department, IIS-Fundación Jiménez Diaz, Madrid, Spain.
R
R
Manso
Pathology Department, IIS-Fundación Jiménez Diaz, Madrid, Spain.
P
P
González-Alonso
Pathology Department, IIS-Fundación Jiménez Diaz, Madrid, Spain.
F
F
Rojo
Translational Oncology Division, Oncohealth Institute, IIS-Fundación Jiménez Diaz, UAM, University Hospital 'Fundación Jiménez Diaz', Madrid, Spain.
J
J
García-Foncillas
D001324:Autoantigens; D004268:DNA-Binding Proteins; D005069:Evaluation Studies as Topic; D056488:Histone Chaperones / Q000037:antagonists & inhibitors*; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000201:enzymology*; D008565:Membrane Proteins / Q000037:antagonists & inhibitors*; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D014157:Transcription Factors / Q000037:antagonists & inhibitors*
D001324:Autoantigens; C500266:CIP2A protein, human; D004268:DNA-Binding Proteins; D056488:Histone Chaperones; D047908:Intracellular Signaling Peptides and Proteins; D008565:Membrane Proteins; D047428:Protein Kinase Inhibitors; C513473:SET protein, human; D014157:Transcription Factors; D011505:Protein-Tyrosine Kinases